Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | BCL2 | P10415 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9154110 | 0.88 | — | — | |
| Xanthine SCHEMBL9443796 | 0.79 | MEN1 (0.34) | LMNAMEN1KMT2ACSNK2A2RAB9A | |
| Xanthine SCHEMBL918381 | 0.79 | MEN1 (0.34) | LMNAMEN1KMT2ACSNK2A2RAB9A | |
| SCHEMBL1275415 | 0.79 | KDM4E (0.31) | MEN1KMT2ACSNK2A2RAB9ACSNK2B | |
| Isoguanine SCHEMBL887740 | 0.76 | PARP1 (0.36) | LMNAMEN1KMT2ACSNK2A2RAB9A | |
| SCHEMBL218201 | 0.76 | CSNK2A1 (0.37) | CSNK2A2CSNK2A1DYRK1A | |
| SCHEMBL16146852 | 0.76 | MEN1 (0.36) | MEN1KMT2ACSNK2A2RAB9ACSNK2B | |
| SCHEMBL1371017 | 0.76 | PDPK1 (0.31) | — | |
| Thioguanine SCHEMBL218891 | 0.76 | PDPK1 (0.37) | — | |
| SCHEMBL16146330 | 0.76 | CSNK2A1 (0.33) | LMNAMEN1KMT2ACSNK2A2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| US-6369208-B1 | INFLUENZA ENDONUCLEASE APATAMER THAT INHIBITS INFLUENZA ENDONUCLEASE AND IS RESISTANT TO CLEAVAGE BY SAID ENZYME | MERCK & CO., INC. | 2002-04-09 | — | — | US | claimed |
| JP-3257675-B2 | — | — | 2002-02-18 | — | — | JP | claimed |
| US-5817635-A | RNA MOLECULES WITH CATALYTIC ACTIVITY | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1998-10-06 | — | — | US | claimed |
| EP-0552178-B1 | MODIFIED RIBOZYMES | MAX PLANCK GESELLSCHAFT (DE) | 1997-01-02 | — | — | EP | claimed |
| EP-0552178-A1 | MODIFIED RIBOZYMES. | MAX PLANCK GESELLSCHAFT (DE) | 1993-07-28 | — | — | EP | claimed |
| WO-1992007065-A1 | MODIFIED RIBOZYMES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1992-04-30 | — | — | WO | claimed |
| US-20260056202-A1 | USE OF MODIFIED PHAGE FOR CAPTURING AND SUBTYPING OF CANCER CELLS | UNIV HONG KONG CHINESE (CN) | 2026-02-26 | — | — | US | disclosed |
| US-12553054-B2 | Compositions and methods related to nucleic acid anticoagulants | NORTH CAROLINA STATE UNIVERSITY (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260009038-A1 | COMPOSITIONS AND METHODS RELATED TO NUCLEIC ACID SENSORS | UNIV ARIZONA STATE (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4605550-A2 | COMPOSITIONS AND METHODS RELATED TO NUCLEIC ACID SENSORS | Arizona Board of Regents on behalf of Arizona State University (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250188517-A1 | COMPOSITIONS AND METHODS RELATED TO NUCLEIC ACID SENSORS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2025-06-12 | — | — | US | disclosed |
| CN-112955553-B | Compositions and methods relating to nucleic acid anticoagulants | 北卡罗来纳大学 | 2025-03-14 | — | — | CN | disclosed |
| US-5213972-A | Production of thymidine and deoxyuridine, intermediates for AZT | CHEMGEN CORPORATION (US) | 1993-05-25 | — | — | US | disclosed |
| US-5164390-A | Cardiac disorders | ORTHO PHARMACEUTICAL CORPORATION (US) | 1992-11-17 | — | — | US | disclosed |
| WO-1992007065-A1 | MODIFIED RIBOZYMES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1992-04-30 | — | — | WO | disclosed |
| US-5021574-A | Cardiotonic agents, antiarrhythmia agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-06-04 | — | — | US | disclosed |
| US-4294920-A | PEPTIZATION, PROTECTIVE COLLOIDS | AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) | 1981-10-13 | — | — | US | disclosed |
| EP-0005200-B1 | SILVER HALIDE PHOTOGRAPHIC MATERIAL AND METHOD OF PREPARATION | Agfa-Gevaert AG (DE) | 1981-04-15 | — | — | EP | disclosed |
| EP-0005200-A2 | Silver halide photographic material and method of preparation | Agfa-Gevaert AG (DE) | 1979-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | LMNA 599/4885MEN1 3276/4885KMT2A 3050/4885 |
| US-20260009038-A1 | COMPOSITIONS AND METHODS RELATED TO NUCLEIC ACID SENSORS | ADAR, ADA, YARS1 | LMNA 527/4885MEN1 4266/4885KMT2A 2402/4885 |
| US-12553054-B2 | Compositions and methods related to nucleic acid anticoagulants | NSUN2, NSUN3, ADAR | LMNA 636/4885MEN1 2083/4885KMT2A 859/4885 |
| US-20260056202-A1 | USE OF MODIFIED PHAGE FOR CAPTURING AND SUBTYPING OF CANCER CELLS | DNMT3A, SELPLG, TP53 | LMNA 727/4885MEN1 3640/4885KMT2A 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.